Inventor · disambiguated record
Tamlyn Neben
Also filed as: NEBEN TAMLYN · NEBEN TAMLYN YEE
12 granted patents·1 pending application·390 citations·filing 1996–2014
93Inventor score
Top patents by PatentIndex Score
13 records- 0196US5710023AIL-13 cytokine receptor chainGENETICS INST·Filed 1996·Granted Jan 20, 1998·131 cites·21 claims
- 0294US7078494B1Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 bindingGENETICS INST LLC·Filed 2000·Granted Jul 18, 2006·43 cites·29 claims
- 0390US7674591B2Methods of using antibodies to human IL-13bc for inhibiting IL-13 bindingGENETICS INST LLC·Filed 2006·Granted Mar 9, 2010·8 cites·31 claims
- 0490US7553487B2Method and compositions for treating asthmaGENETICS INST LLC·Filed 2004·Granted Jun 30, 2009·36 cites·25 claims
- 0587US7282206B2Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chainsUS HEALTH·Filed 2003·Granted Oct 16, 2007·24 cites·34 claims
- 0686US6664227B1Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chainsINST GENETICS LLC·Filed 1999·Granted Dec 16, 2003·61 cites·32 claims
- 0784US6214559B1Methods of identifying inhibitors of binding of IL-13 to the IL-13 receptor chainGENETICS INST·Filed 1997·Granted Apr 10, 2001·32 cites·5 claims
- 0880US6268480B1IL-13 Receptor chainGENETICS INST·Filed 1997·Granted Jul 31, 2001·23 cites·15 claims
- 0980US6248714B1Methods of inhibiting binding and treating Ig-mediated responses with IL-13 receptorGENETICS INST·Filed 1997·Granted Jun 19, 2001·25 cites·15 claims
- 1065US9951126B2Antibodies directed against nerve growth factor (NGF)ANAPTYSBIO INC·Filed 2014·Granted Apr 24, 2018·0 cites·2 claims
- 1158US2010086516A1Cytokine receptor chainGENETICS INST LLC·Filed 2009·Application pending·0 cites
- 1257US8926978B2Antibodies directed against nerve growth factor (NGF)ANAPTYSBIO INC·Filed 2012·Granted Jan 6, 2015·0 cites·2 claims
- 1348US7507706B1Cytokine receptor chainGENETICS INST LLC·Filed 1999·Granted Mar 24, 2009·7 cites·23 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →